new onset atrial fibrillation and paroxysmal atrial fibrillation
Conditions
Interventions
Trade Name: Solu-Cortef 100mg inj kuiva-aine ja liuotin liuosta varten
Product Name: Solu-Cortef
Product Code: 420596
Pharmaceutical Form: Concentrate and solvent for solution for infusion
Pharmaceuti
Sponsors
Kuopio University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Coronary artery bypass surgery or aortic valve surgery, adult, willing to participate, not in chronic atrial fibrillation preoperatively Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 120 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 120
Exclusion criteria
Exclusion criteria: not willing to participate, insulin dependent diabetes, active peptic ulcer, oversensitivity or allergy to hydrocortison or metoprolol, chronic atrial fibrillation, psychosis, prolonged stay in intensive care unit postoperatively
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The main objective of the trial is to investigate whether postoperative corticosteroid and betablocker management prevents new-onset atrial fibrillation or activation of paroxysmal atrial fibrallation immediately after coronary artery bypass surgery and aortic valve surgery.;Secondary Objective: Not applicable;Primary end point(s): Patient stays in sinus rhythm for three days postoperatively or patient gets atrial fibrillation during first three postoperative days.;Timepoint(s) of evaluation of this end point: Three postoperative days | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): none;Timepoint(s) of evaluation of this end point: none | — |
Countries
Australia, Estonia, Finland
Contacts
Public Contacttutkijalääkäri Visa Mahlamäki
Kuopio University Hospital
Outcome results
None listed